MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease

    J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, K. Kelemen, I. Mihály, S. Szatmári (TARGU MURES, Romania)

    Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…
  • 2025 International Congress

    Down-titration of levodopa complicated by catatonia

    D. Newbold, . (New York, USA)

    Objective: Provide evidence that reductions in levodopa can trigger catatonia Background: Dopamine dysregulation syndrome (DDS) occurs when patients crave and self-up-titrate levodopa, often leading to…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication

    T. Denne (Mission Viejo, USA)

    Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…
  • 2025 International Congress

    Efficacy of LSVT-BIG Treatment Compared to Other Physiotherapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    A. Amin, M. Helal, A. Alsokery, H. Sabet, A. Ibrahim, A. Suleiman, I. Yakout, A. Abunamoos, M. Elsayed (Cairo, Egypt)

    Objective: We aim is to assess the efficacy of Lee Silverman Voice Treatment-BIG therapy (LSVT-BIG) compared to other physiotherapy in patients with Parkinson's Disease (PwP).…
  • 2025 International Congress

    Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease

    M. Messak, A. Abdelmageed, Y. Khattab (Helwan, Egypt)

    Objective: Evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) agonists on Parkinson’s disease (PD). Background: The idea of ​​repositioning drugs used to treat PD…
  • 2025 International Congress

    Botulinium toxin in treatment of Parkinsonism

    A. Wankar (Nagpur, India)

    Objective: This review discusses the use of BT in various motor and non-motor symptoms of Parkinsonism. This review discusses the use of BT in various…
  • 2025 International Congress

    Boosting Education and Awareness Together for people with Parkinson’s Disease (BEATs-PD): Methodological Considerations in Research Co-Creation

    R. Khamishon, K. Devlin, B. Advisory Board, K. Kang, L. Currens, E. Lu, S. Phelan, E. Choi, S. Willoughby, A. Pantelyat, K. Mills (Baltimore, USA)

    Objective: To describe methodological considerations related to stakeholder engagement in community-based participatory research (CBPR) to create a dance and music-based program (DMBP) for people with…
  • 2025 International Congress

    Effects of Exogenous Melatonin on Sleep and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    M. Alghaniem, A. Abunamoos, F. Qtaishat, A. Rababah, M. Abu Hasna, Y. Aljazi, M. Mustafa, F. Alnajjar, T. Patel, N. Hamam (Amman, 11942, Jordan)

    Objective: To evaluate melatonin's efficacy in enhancing sleep and motor symptoms in Parkinson’s disease (PD) through an updated systematic review and meta-analysis. Background: Sleep disturbances…
  • 2025 International Congress

    Artificial Intelligence for Understanding Parkinson Disease State and Patient Stratification Using CSF Proteomics

    L. Abu Zohair, H. Zantout, M. Vallejo, M. Uddin (Edinburgh, United Kingdom)

    Objective: The objective of this research is to employ an Artificial Intelligence (AI) approaches to identify patient status and disease states in neurodegenerative diseases (NDDs),…
  • « Previous Page
  • 1
  • …
  • 371
  • 372
  • 373
  • 374
  • 375
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley